^
Association details:
| Biomarker: | RNF43 mutation + MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2226 / 8 - Precise stratification of immunotherapy outcomes using response-associated somatic mutations
Published date:
05/27/2020
Excerpt:
All patients had received at least one dose of an ICI (anti-PD-1/PD-L1, anti-CTLA-4 or both)...When stratifying by MSI status, we found that RNF43 was independently associated with improved survival among MSI-H COADREAD patients.
